TLX Stock Overview
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Telix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$12.54 |
| 52 Week High | AU$13.54 |
| 52 Week Low | AU$8.20 |
| Beta | 2.35 |
| 1 Month Change | 0.32% |
| 3 Month Change | 14.00% |
| 1 Year Change | 33.83% |
| 3 Year Change | 216.67% |
| 5 Year Change | 1,316.95% |
| Change since IPO | 1,528.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 1.3% | -2.1% | -2.8% |
| 1Y | 33.8% | -8.1% | 4.0% |
Return vs Industry: TLX exceeded the Australian Biotechs industry which returned -8.1% over the past year.
Return vs Market: TLX exceeded the Australian Market which returned 4% over the past year.
Price Volatility
| TLX volatility | |
|---|---|
| TLX Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.4% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: TLX's share price has been volatile over the past 3 months.
Volatility Over Time: TLX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 234 | Chris Behrenbruch | telixpharma.com |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent.
Telix Pharmaceuticals Limited Fundamentals Summary
| TLX fundamental statistics | |
|---|---|
| Market cap | AU$4.21b |
| Earnings (TTM) | AU$5.21m |
| Revenue (TTM) | AU$502.55m |
795.2x
P/E Ratio8.2x
P/S RatioIs TLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLX income statement (TTM) | |
|---|---|
| Revenue | AU$502.55m |
| Cost of Revenue | AU$188.16m |
| Gross Profit | AU$314.39m |
| Other Expenses | AU$309.18m |
| Earnings | AU$5.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.016 |
| Gross Margin | 62.56% |
| Net Profit Margin | 1.04% |
| Debt/Equity Ratio | 6.2% |
How did TLX perform over the long term?
See historical performance and comparison